Across TCGA pan-cancer cohorts, TM6SF2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TM6SF2 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TM6SF2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TM6SF2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, LUAD, and OV are the cancer types where TM6SF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.115	0.659	<.001	42	view →
LUAD	OS	Median	All	0.386	0.815	<.001	22	view →
OV	OS	Median	All	0.361	0.842	.004	18	view →
UCEC	DFS	Median	II,III,IV	1.000	0.442	.028	14	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TM6SF2 tumor-vs-normal RNA expression · all TM6SF2 data types